DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Their core work

The German Cancer Research Center (DKFZ) in Heidelberg is Germany's largest biomedical research institution dedicated to understanding the mechanisms of cancer and translating findings into improved diagnostics, therapies, and prevention strategies. Their work spans fundamental tumor biology — dissecting how cancers develop, resist treatment, and metastasize — through to computational approaches like radiomics, bioinformatics, and multi-omics data integration. They are a major force in pediatric oncology, immunotherapy, and precision medicine, and increasingly serve as a hub for building FAIR-compliant research data infrastructures across Europe. Beyond discovery research, they contribute to clinical strategy through patient stratification, biomarker development, and drug target identification.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), DKFZ focused heavily on breast cancer biology, molecular subtyping, risk stratification, and foundational biomedical research infrastructure (CORBEL, BBMRI-ERIC). The later period (2019–2024) shows a clear shift toward computational and data-centric cancer research — bioinformatics, single-cell sequencing, integrative multi-omics analysis, and FAIR data sharing became dominant themes. There is also a notable pivot toward immunotherapy (immune repertoires, therapeutic antibodies) and epitranscriptomics, signaling a move from purely mechanistic tumor biology toward translational immune-oncology and data-driven precision medicine.

DKFZ is moving from classical molecular cancer research toward computational, data-intensive, and immune-focused approaches — future partners should expect strong bioinformatics and FAIR data capabilities alongside deep oncology expertise.

How they like to work

DKFZ operates as both a consortium leader and a valued specialist partner — they coordinate 30 of 65 projects (46%), an unusually high leadership rate for a research center. Their 21 ERC grants reflect strong individual PI-driven research, while their participation in large health consortia (B-CAST, MESI-STRAT, ITCC-P4) shows willingness to embed in multi-partner collaborations. With 476 unique consortium partners across 45 countries, they function as a major European hub rather than a closed network, making them accessible but also selective collaborators.

DKFZ has collaborated with 476 distinct partners across 45 countries, making it one of the most broadly connected cancer research institutions in Europe. Their network spans from clinical centers and universities to biobank infrastructures and data platforms, with particularly dense connections across Western Europe.

What sets them apart

DKFZ combines the scale and depth of Germany's largest dedicated cancer research center with an exceptionally strong ERC portfolio (21 grants), which is rare even among top European research institutions. They bridge fundamental tumor biology and translational precision medicine while increasingly building the computational and data infrastructure needed for modern oncology. For consortium builders, DKFZ offers both scientific credibility and operational leadership — nearly half their projects are self-coordinated, meaning they bring project management muscle alongside world-class research.

Highlights from their portfolio

• BARCODED-CELLTRACING
  EUR 2.5M ERC grant — their largest single award — pioneering in vivo fate mapping of blood and immune cell development using endogenous genetic barcoding.
• ITCC-P4
  Major coordinated pediatric cancer platform (EUR 1.7M) building preclinical proof-of-concept infrastructure with PDX models, organoids, and biomarker discovery across European partners.
• REBUILDCNS
  EUR 2M ERC grant tackling brain injury repair through glial progenitor reprogramming — demonstrates reach beyond classical oncology into neuroscience and regenerative medicine.